Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: The mortality, length of hospitalization, and costs associated with invasive fungal infections (IFIs) in hospitalized patients were studied. METHODS: This retrospective database study used data from the 2004 Healthcare Cost and Utilization Project Nationwide In-patient Sample. Patients were selected for inclusion based on diagnostic codes corresponding to an IFI. A control group was matched to the IFI group based on high-risk conditions (i.e., cancer, infection with human immunodeficiency virus, chronic obstructive pulmonary disease, diabetes mellitus, and solid-organ, hematopoietic stem cell, or bone marrow transplant), age, sex, and hospital region and teaching status. Excess mortality, length of hospital stay, and costs were estimated as the differences between the IFI and control groups. RESULTS: A total of 11,881 patients were identified with a discharge diagnosis of an IFI who could be matched to a control. Frequent infections included candidiasis (40.2%), other mycoses (36.3%), and aspergillosis (16.4%). Patients with IFIs had a significantly higher mortality rate (15% versus 5%), mean +/- S.E. length of stay (18.7 +/- 0.4 days versus 7.3 +/- 0.1 days), and mean +/- S.E. costs ($44,726 +/- $1,255 versus $15,445 +/- $404) (p < 0.001 for all comparisons) than did patients without IFIs. The burden of IFIs varied by high-risk condition (highest for transplant recipients and patients with cancer) and type of infection (highest for candidiasis, zygomycosis, and aspergillosis). CONCLUSION: Examination of a large database showed that, compared with high-risk patients without IFIs, those with IFIs had higher mortality, a longer hospital stay, and higher costs associated with their hospitalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Chang, D. C., Burwell, L. A., Lyon, G. M., Pappas, P. G., Chiller, T. M., Wannemuehler, K. A., Fridkin, S. K., & Park, B. J. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/524324 · Cited by 51
Cited by
Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., Che, D., & Dromer, F. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.140087 · Cited by 426
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Hong, D. K., Blauwkamp, T. A., Kertesz, M., Bercovici, S., Truong, C., & Banaei, N. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.06.009 · Cited by 201
Epidemiology of invasive fungal diseases on the basis of autopsy reports
Dignani, M. C. (2014) · F1000Prime Reports · doi:10.12703/p6-81 · Cited by 73
“aspergillosis at 12 weeks of therapy [8]); d) they may require surgery; e) treatments are prolonged (from weeks to months or years); f) the delay of their treatment is associated with an increased mortality rate [9]; g) they may relapse after apparent cure if a subsequent period of immunosuppression occurs (in this ca…”
Background
Metadata
- Authors
- Menzin, J., Meyers, J. L., Friedman, M., Perfect, J. R., Langston, A. A., Danna, R. P., & Papadopoulos, G.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-01
- Volume
- 66
- Issue
- 19
- Pages
- 1711-1717
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W1986071890
- Cited by
- 151
- References
- 4
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. https://app.cochat.ai/papers/10.2146/ajhp080325
- The paper
- Menzin, J., Meyers, J. L., Friedman, M., Perfect, J. R., Langston, A. A., Danna, R. P., & Papadopoulos, G. (2009). Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. American Journal of Health-System Pharmacy. https://doi.org/10.2146/ajhp080325
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.